What is it about?
The transfusion of plasma containing anti-A and anti-B to the Group A or B transfusion recipient can be associated with an unexplained clinically significant hemolytic event. Using an in vitro model, we show that complement-mediated hemolysis can go undetected because the population of red cells with the defect can be completely hemolysed, giving a false negative test for hemolysis.
Featured Image
Why is it important?
There are disease states where defects in the regulators of complement are acquired. The acquired defect in the regulators of complement, DAF and MIRL, is termed paroxysmal hemoglobinuria, which can be found in patients with myelodysplastic syndrome and aplastic anemia.
Perspectives
The typical test for complement-mediated hemolysis is the Direct Antiglobulin Test (DAT). It is important to do other specific laboratory testing to rule out PNH as a cause of unexplained hemolysis after the transfusion of ABO incompatible plasma. The DAT
Gregory Denomme
BloodCenter of Wisconsin
Read the Original
This page is a summary of: Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions, Blood Advances, October 2017, American Society of Hematology,
DOI: 10.1182/bloodadvances.2017008805.
You can read the full text:
Contributors
The following have contributed to this page
